Showing results (2831-2840 of 3,717) with videos related to
Sort By:
Pageof 372
Investigational New Drugs|January 20, 2011
Phase I trial of sorafenib in combination with interferon-alpha in Japanese patients with unresectable or metastatic renal cell carcinomaMasashi Niwakawa, Katsuyoshi Hashine, Raizo Yamaguchi, et al.Investigational New Drugs|June 4, 2019
Effects of chemotherapy on placental development and function using in vitro culture of human primary cytotrophoblastsChristophe Louis Depoix, Arthur Colson, Mina Mhallem-Gziri, et al.Investigational New Drugs|June 8, 2019
A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with advanced adrenal cortical carcinomaHao Xie, Jun Yin, Manisha H Shah, et al.Investigational New Drugs|January 1, 1997
Multiple resistance modulators combined with carboplatin for resistant malignancies: a pilot studyD J Stewart, R Goel, M C Cripps, et al.Investigational New Drugs|January 1, 1997
IL-4R expression in AIDS-KS cells and response to rhIL-4 and IL-4 toxin (DAB389-IL-4)J Cai, T Zheng, J Murphy, et al.Investigational New Drugs|July 22, 2016
A phase I trial of cabozantinib and gemcitabine in advanced pancreatic cancerDavid B Zhen, Kent A Griffith, Joshua M Ruch, et al.Investigational New Drugs|April 24, 2015
A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancerAnalia Azaro, Jordi Rodon, Antonio Calles, et al.Investigational New Drugs|January 1, 1984
A method for the simultaneous measurement of the new anthracycline derivative 4'-deoxydoxorubicin and its metabolites by reversed phase liquid chromatographyY M Peng, D S Alberts, S E Salmon, et al.Investigational New Drugs|January 1, 1984
Phase I trial of 4'-deoxydoxorubicin given weeklyC Sessa, L Bosia, S Kaplan, et al.Investigational New Drugs|January 1, 1984
Southwest Oncology Group study of Mitoxantrone for treatment of patients with advanced squamous cell carcinoma of the head and neckD E Mattox, G M Clark, S P Balcerzak, et al.Pageof 372